INS and type 2 diabetes mellitus: Empagliflozin in doses of 10 mg or 25 mg for 52 weeks as an add-on therapy to liraglutide in Japanese patients with T2DM insufficiently controlled by liraglutide alone in a phase 4 trial by Terauchi et al. [99] led to improvements in glycemic control (reduction in HbA1c and fasting plasma glucose levels), decreased body weight, waist circumference, SBP and DBP as well as reduction in fasting plasma insulin levels [99].